ay mortality rate only in patients with enhanced coagulopathy risk such as SIC score of 4 or greater (Tang, Bai, et al., 2020)
• Antiplatelet and anticoagulant combination therapy for hypoxemia, respiratory failure, and cardiac adverse ev